Savient Pharmaceuticals, Inc. (Savient), incorporated in 1980, is a specialty biopharmaceutical company focused on commercializing KRYSTEXXA (pegloticase) in the United States and completing the development and seeking regulatory approval outside of the United States for KRYSTEXXA, particularly in the European Union. The Company also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. In October 2013, the Company announced that it has elected to file voluntary petitions under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (the Court). Effective January 10, 2014, Crealta Pharmaceuticals LLC, a majority owned unit of GTCR LLC acquired Savient Pharmaceuticals Inc.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NASDAQ:SVNT
- CUSIP: N/A
- Web: N/A
- 50 Day Moving Avg: $43.10
- 200 Day Moving Avg: $37.63
- 52 Week Range: $14.90 - $50.85
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -44.50
- P/E Growth: 0.00
- Average Volume: 104,033 shs.
Frequently Asked Questions for Savient Pharmaceuticals (NASDAQ:SVNT)
What is Savient Pharmaceuticals' stock symbol?
Savient Pharmaceuticals trades on the NASDAQ under the ticker symbol "SVNT."
Who are some of Savient Pharmaceuticals' key competitors?
Some companies that are related to Savient Pharmaceuticals include Partnership Assurance Group PLC (PA), Merck & Co. (MRK), AstraZeneca plc (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Merck KGaA (MKGAY), Shire PLC (SHP), Hospira (HSP), Smith & Nephew plc (SN), Omnicare (OCR), ConvaTec Group PLC (CTEC), Mediclinic International PLC (MDC), Health Net (HNT), Patheon NV (PTHN), NMC Health PLC (NMC), Catalent (CTLT), Cotiviti Holdings (COTV) and Puma Biotechnology (PBYI).
How do I buy Savient Pharmaceuticals stock?
Shares of Savient Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Savient Pharmaceuticals' stock price today?
MarketBeat Community Rating for Savient Pharmaceuticals (NASDAQ SVNT)MarketBeat's community ratings are surveys of what our community members think about Savient Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Savient Pharmaceuticals stock can currently be purchased for approximately $40.05.
Consensus Ratings for Savient Pharmaceuticals (NASDAQ:SVNT) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Savient Pharmaceuticals (NASDAQ:SVNT)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Savient Pharmaceuticals (NASDAQ:SVNT)Earnings History by Quarter for Savient Pharmaceuticals (NASDAQ SVNT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/14/2013||Q2 2013||($0.31)||($0.35)||$5.84 million||$6.10 million||View||N/A|
|5/15/2013||Q1 2013||($0.31)||($0.34)||$5.65 million||$4.70 million||View||N/A|
|3/19/2013||Q4 2012||($0.44)||($0.39)||$6.18 million||$4.95 million||View||N/A|
|11/8/2012||Q312||($0.45)||($0.56)||$5.87 million||$4.91 million||View||N/A|
Earnings Estimates for Savient Pharmaceuticals (NASDAQ:SVNT)
Current Year EPS Consensus Estimate: $-1.18 EPS
Next Year EPS Consensus Estimate: $-0.90 EPS
Dividend History for Savient Pharmaceuticals (NASDAQ:SVNT)
No dividend announcements for this company have been tracked by MarketBeat.com
Headline Trends for Savient Pharmaceuticals (NASDAQ:SVNT)
Latest Headlines for Savient Pharmaceuticals (NASDAQ:SVNT)
|SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Filing of a Complaint Concerning the Fairness of the Sale of Seventy Seven Energy, Inc. to Patterson-UTI, Inc. -- SVNT|
finance.yahoo.com - May 2 at 5:55 PM
|Zacks: Savient Pharmaceuticals Inc (SVNT) Given Consensus Recommendation of "Hold" by Analysts|
www.americanbankingnews.com - April 4 at 10:27 PM
|SEVENTY SEVEN ENERGY INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibi|
biz.yahoo.com - February 23 at 9:07 PM
|SEVENTY SEVEN ENERGY INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure|
biz.yahoo.com - November 9 at 10:35 AM
|Seventy Seven Operating LLC -- Moody's downgrades Seventy Seven's incremental term loan to Caa2|
www.moodys.com - October 24 at 7:13 PM
|SEVENTY SEVEN ENERGY INC. Financials|
finance.yahoo.com - October 1 at 6:35 PM
|Seventy Seven Operating LLC -- Moody's assigns Caa1 CFR to Seventy Seven Operating LLC; stable outlook|
www.moodys.com - September 28 at 11:33 AM
|SEVENTY SEVEN ENERGY INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh|
biz.yahoo.com - September 27 at 7:28 PM
|SEVENTY SEVEN ENERGY INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Prin|
biz.yahoo.com - September 23 at 6:55 PM
Savient Pharmaceuticals (SVNT) Chart for Monday, July, 24, 2017